6 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow RDEA3170 10 mg: new trials by email Literature Review of RDEA3170 10 mg trials Research Report on RDEA3170 10 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RDEA3170 Bioavailability Study RDEA3170 10 mg, RDEA3170 2.5 mg - Gout | Phase 1 | Completed | Ardea Biosciences, Inc. | 15 | 2014-11-01 | 2017-10-13 |
| RDEA3170 and Allopurinol Combination Study in Gout Subjects RDEA3170 10 mg, allopurinol 300 mg - Gout | Phase 1 | Completed | Ardea Biosciences, Inc. | 12 | 2014-11-01 | 2017-12-20 |
| RDEA3170 and Febuxostat Combination Study in Gout Subjects RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5 - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 64 | 2014-10-01 | 2017-07-27 |
| RDEA3170 AME Study RDEA3170 10 mg - Healthy | Phase 1 | Completed | Ardea Biosciences, Inc. | 8 | 2013-08-01 | 2014-01-09 |
| RDEA3170 Monotherapy in Subjects With Gout Placebo, RDEA3170 5 mg, RDEA3170 10 mg - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 172 | 2013-08-01 | 2015-07-01 |
| RDEA3170 and Febuxostat Drug Interaction Study RDEA3170 10 mg, Febuxostat 40 mg, placebo - Healthy | Phase 1 | Completed | Ardea Biosciences, Inc. | 21 | 2013-06-01 | 2014-01-09 |
Gout (4)
United States (6)
J. Hall, MD (3) · S. Baumgartner (2) · J. Hall (1)